Antiviral therapy of herpes simplex and varicella-zoster virus infections

Intervirology

Volumn 40, Issue 5-6, 1997, Pages 343-356

  Wutzler, Peter ^a  

^a Institute for Antiviral Chemotherapy   (Germany)

Author keywords

Aciclovir; Brivudin; Famciclovir; Foscarnet; Herpes encephalitis; Herpes genitalis; Herpes labialis; Herpes zoster; Sorivudine; Valaciclovir; Varicella

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ANTIVIRUS AGENT; FAMCICLOVIR; SORIVUDINE; VALACICLOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; HERPES SIMPLEX; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS;

2-AMINOPURINE; ACYCLOVIR; ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; BROMODEOXYURIDINE; CHICKENPOX; DRUG RESISTANCE, MICROBIAL; ENCEPHALITIS, VIRAL; HERPES GENITALIS; HERPES LABIALIS; HERPES SIMPLEX; HERPES ZOSTER; HUMANS; IMMUNOCOMPROMISED HOST; PRODRUGS; SIMPLEXVIRUS; VALINE;

EID: 2642705014     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000150567     Document Type: Article

References (112)

1. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ: Selectivity of action of an antihcrpctic agent, 9-(2-hydroxy-cthoxymethvDguaninc, Proc Natl Acad Sci USA 1977;74:5716-5720.
2. Reardon JE, Spcctor T: Herpes simplex virus type I polymerase, Mechanism of inhibition by acyclovir triphosphate, J Biol Chem 1989;264: 7405-7411.
3. Tilson HH, Engle CR, Andrews EB; Safety of acyclovir: A summary of the first 10 years experience, J Med Virol 1993:suppl 1:67-73.
4. Jaobson MA: Valacidovir (BW256U87): The i-valyl ester of acyclovir, J Med Virol 1993: suppi 1:150-153.
5. Weller S, Blum MR, Doucette M, Burnette T, Cedcrberg DM, de Miranda P, Smiley ML: Pharmacokinetics of the acyclovir pro-drug valacidovir alter escalating single- and mulli-ple-dose administration to normal volunteers, Clin Pharmacol Thcr 1993:54:595-605.
6. Spruance SL, Tyring AK, DcGregori B, Miller C, Beutner K, and the Valacidovir HSV Study Group: A large-scale, placebo-controlled, dosc-ranging trial of peroral valacidovir for episodic treatment of recurrent herpes genitalis, Arch Intern Med 1996:156:1729-1735.
7. Patel R, Bodsworlh NJ, Woolley P, Peters P, Vejlsgaard G, Saari S, Gibb A, Robinson J and the International Valacidovir Study Group: Valacidovir for the suppression of recurrent genital HSV infection: A placebo-controlled study of once-daily therapy, Genitourin Hed 1997;73:105-109.
8. Boyd MR, Bacon TH, Sutton D, Cole M: Antiherpesvirus activity of 9-(4-hydroxy-3-hvdrox-ymcthylbut-l-vl)guanine (BRL 39123) in cell culture, Antimicrob Agents Chemother 1987: 31:1238-1242.
9. Verc Hodge RA, Sutton D, Boyd MR, Hamden MR, Jarvest RL: Selection of an oral prodrug (BRL428I0: famciclovir) for the antiherpcsvi-rusagent BRL 39123 [9-(4-hydroxy-3-hydroxy-methylbut-l-yl)guaninc; pcnciclovir), Antimicrob Agents Chemother 1989:33:1765-1773.
10. Vere Hodge RA, Cheng Y-C: The mode of action of pcnciclovir, Antiviral Client Chemother 1993;4(suppl I): 13-24.
11. Pue MA, Benct LZ: Pharmacokinetics of fami-ciclovir in man, Antiviral Client Chemother 1993:4(suppl 1):47-55.
12. Saltzman R, Jurcwicz R, Boon R: Safety of famciclovir in patients with herpes zoster and genital herpes, Antimicrob Agents Chemother 1994:38:2454-2457.
13. De Clercq E, Descampcs J, dc Somer P, Barr PJ, Jones AS, Walker RT: (E)-5-(2-bromovi-nyl)-2'dcoxyuridine: A potent and selective anti-herpes agent, Proc Natl Acad Sci USA 1979;76:2947-2951.
14. Machida H, Sakata S, Kuninaka A,: Yoshino H Antihcrpesviral and anticellular effects of l-beta-D-arabinofuranosyl-E-5-(2-halogenovi-nyl)uracils, Antimicrob Agents Chemother 1981:20:47-52.
15. Pavan-Langslon D, Foster CS: Trifiuorothy-niidine and idoxuridinc therapy of ocular herpes, Am J Ophthalmol 1977:84:818-825.
16. Fyfc J A: Differential phosphorylation of (E)-5-(2-bromovinyl)-2')-deoxyuridine monophosphate by thymidilate kinases from herpes simplex viruses types I and 2 and varicclla-zoster virus, Mol Pharmacol 1982:21:432-437.
17. Mancini WR, De Clercq E, Prusol TWH: The relationship between incorporation of(E)-5-(2-bromovinyl)-2'-dcoxyuridinc into herpes virus type I DNA with virus infectivity and DNA integrity, J Biol Chem 1983:258:792-795.
18. Sagi J, Czuppon A, Katjar M, Szabolcs A, Sze-mo A, Otvos L: Modified polynucleotides, IV, Properties of a synthetic DNA containing the anti-herpes agent (E)-5-(2-bromovinyl)-2'-deoxvuridine, Nucleic Acids Res 1982:10: 6051-6066.
19. Shigcla S, Yokota T, Iwabuchi T, Baba M, Konno K, Ogata M, Dc Clercq E: Comparative efficacy of antiherpes drugs against various strains of varicella-zostcr virus, J Infect Dis 1983:147:576-584.
20. Desgranges C, Razaky G, Drouillet F, Bricaud H, Hcrdcwijn P, De Clercq E: Regeneration of the antiviral drug (E)-5-(2-bromovinyl)-2'-dcoxyuridine in vivo, Nucleic Acid Res, 1984: 12:2081-2090.
21. Desgranges C, Razaka G, De Clercq E, Herde-wijn H, Balzarini J, Drouillet F, Bricaud H: Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-flurouracil in rats and leukemic mice, Cancer Res 1986:64: 1094-1101.
22. Wutzlcr P, Dc Clercq E, Wutke K, Fiirbcr I: Oral brivudin vs, intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: A randomized double-blind trial, J Med Virol 1995:46:252-257.
23. Machida H: Brovavir: Its antihcrpesviral activity and mode of action, Adv Exp Med Biol 1990;278:255-265.
24. Machida H, Nishitani M: Drug susceptibilities of isolates of varicella-zostcr virus in a clinical study of oral brovavir, Microb Immunol 1990: 34:407-411.
25. Wallace MR, Chamberlin CJ, Sawyer MH, Ar-vin AM, Harkins J, LaRoeco A, Colopy MW, Bowler WA, Oldfield III EC: Treatment of adult varicella with sorivudine: A randomized, placebo-controlled trial, J Infect Dis 1996:174: 249-255.
26. Hiraoka A, Masaoka T, Nagai K, Horiuchi A, Kanantaru A, Niimura M, Hantada T, Takaha-shi M: Clinical effect of BV-araU on varicclla-zoster virus infection in immunocompromised patients with haematological malignancies, J Antimicrob Chemother 1991:27:361-367.
27. I lelgstrand E, Eriksson B, Johansson NG, Lan-ncro B, Larsson A, Misiorny A, Norcn JO, Sjo-bcrg B, Stenberg K, Stening G, Stridh S, Oberg B: Trisodium phosphonoformate, a new antiviral compound, Science 1978:201:819-821.
28. Wagstal TAJ, Bryson HM: Foscamet, A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections, Drugs 1994:48:199-226.
29. De Clercq E, Holy A, Rosenberg I, Sakunta T, Balzarini J, Maudgal PC: A novel selective broad-spectrum anti-DNA virus agent, Nature 1986;323:464-467.
30. De Clercq E, Sakunta T, Baba M, Pauwels R, Balzarini J, Rosenberg 1. Holy A: Antiviral activity of phosphonylmcthoxyalkyl derivatives of purine and pyrimidines, Antiviral Res 1987:8:261-272.
31. Neyts J, Snocck R, Schols D, Balzarini J, De Clercq E: Particular characteristics of the antihuman cytomegalovirus activity of (, S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cyto-sine (HPMPC) in vitro, Antiviral Res 1991:16: 41-52.
32. Katz DH, Marcellctti JF, Khalil MH, Pope LE, Katz LR: Antiviral activity of l-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex, Proc Natl Acad Sci USA 1991: 88:10825-10829.
33. Habbema L, De Boulle K, Rodcrs GA, Katz H: n-Docosanol 10% cream in the treatment of recurrent herpes labialis: A randomised, double-blind, placebo-controlled study, Acta Derm Venercol 1996:76:479-481.
34. 1 for topical treatment of genital and anal herpes simplex lesions in patients with AIDS, Antiviral Res 1997:37: 91-103.
35. Spruance SL, Crumpacker CS: Topical percent acyclovir in polyethylene glycol for herpes simplex labialis, Antiviral effect without clinical benefit, Am J Med 1982:73:315-319.
36. Fiddian AP, lvanvi L: Topical acyclovir in the management of recurrent herpes labialis, Br J Dermatol 1983:109:321-326.
37. Shaw M, King M, Best JM, Banatvala JE, Gibson JR, Klaber MR: Failure of acyclovir cream in treatment of recurrent herpes labialis, Br Med J (Clin Res Ed) 1985 6:291:7-9.
38. Rabom GW, McGaw WT, Grace M, Tyrrell LD, Samuels SM: Oral acyclovir and herpes labialis: A randomized, double-blind, placebo-controlled study, J Am Dent Assoc 1987:115: 38-42.
39. Spruance SL, Stewart JC, Rowe NH, McKeough MB, Wcncrstrom G, Freeman DJ: Treatment of recurrent herpes simplex labialis with oral acyclovir, J Infect Dis 1990; 161:185-190.
40. Lawee D, Rosenthal D, Aoki FY, Portnoy J: Efficacy and safely of foscamet for recurrent orolabial herpes: A multicentre randomized double-blind study, Can Med Assoc J 1988: 138:329-333.
41. Gross G, Stockfleth E, Berg-Drewniok B, Meyer T, Lorkowski G, Zenker O: Topisches Foscamet bei rczidivierendem Herpes labialis, Kontrollierte klinische Studie z, ur Wirksam-keit, Chemother J 1995:(suppl 10):24-29.
42. Spruance SL, Stewart JC, Freeman DJ, Briglu-man VJ, Cox JL, Wenerstrom G, MeKeongh MB, Rowe NH: Early application of topical 15% idoxuridine in dimethyl sulfoxide shortens the course of herpes simplex labialis: A multicenter placebo-controlled trial, J Infect Dis 1990:161:191-197.
43. Spruance SL, for the Penciclovir Topical Col laborative Study Group: Penciclovir cream: A new effective treatment for recurrent herpes simplex labialis, Clinical Dermatology 2000 -An International Congress, Vancouver, Canada, 1996.
44. Raborn GW for the Penciclovir Topical Collaborative Study Group: Penciclovir cream for recurrent herpes simplex labialis: An effective new treatment (abstract No, H81), 36th interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans 1996.
45. Bryson YJ, Dillon M, Lovett M, Acuna G, Taylor S, Cherry JD, Johnson BI, Wicsmeier E, Growdon W, Creagh-Kirk T, Keeney R: Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir: A randomized double-blind controlled trial in normal subjects, N Engl J Med 1983:308:915-921.
46. Mertz GJ, Critchlow CW, Benedetti H, Reich-man RC, Dolin R, Connor J, Redfield DC, Savoia MC, Richman DD, Tyrrell DL, Mied-zinski L, Portnoy J, Keeney RE, Corey L: Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection, JAMA 1984:252:1147-1151.
47. Wald A, Benedetti J, Davis G, Remington M, Winter C, Corey L: A randomized, doubleblind, comparative trial comparing high- and standard-dosc oral acyclovir for first-episode genital herpes infections, Antimicrob Agents Chemother 1994:38:174-176.
48. Five KM, Barbarash RA, Rudolph T, Dcgrego-rio B, Roth R, The Valaciclovir International Herpes Simplex Virus Study Group: Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infections, Results of an international, multicenter, double-blind, randomized clinical trial, Sex Transm Dis 1997: 24:481-486.
49. Loveless M, Harris W, Sacks S: Treatment of first episode genital herpes with famciclovir (abstract No HI2), 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco 1995.
50. Woolley PD: Clinical reactivation of HSV: Differential effects of famciclovir and aciclovir (abstract No, P 1422), 8th European Congress of Clinical Microbiology and Infectious Diseases, Lausanne 1997.
51. Reichman RC, Badger GJ, Mertz GJ, Richman DD, Connor JD, Savoia MC, Oxman MN, Bryson Y, Tyrrell D, Portnoy J, Crcigh-Kirk T, Keeney RE, Ashikaga T, Dolin R: Treatment of recurrent genital herpes simplex infections with oral acyclovir, A controlled trial, JAMA 1984;25:2103-2107.
52. Bodsworth NJ, Crooks RJ, Bcrell S, Vejlsgaard G, Paavoncn J, Worm AM, Uexkull N, Esman J, Strand A, Ingamells AJ, Gibb A and the International Valaciclovir HSV Study Group: Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: A randomised, double-blind trial, Genilourin Med 1997:73:110-160.
53. Sacks SL, Aoki FY, Diaz-Miloma F, Seilors J, Shafran SD, for the Canadian Famciclovir Study Group: Patient-initiated, twice daily oral famciclovir for early recurrent genital herpes, A randomized, double-blind multicenter trial, JAMA 1996:276:44-49.
54. Straus SE, Takiff HE, Seidlin M, Bachrach S, Lininger L, DiGiovanna JJ, Western KA, Smith HA, NusinolT Lehrman S, Creagh-Kirk T, Ailing DW: Suppression of frequently recurring genital herpes, A placebo-controlled double-blind trial of oral acyclovir, N Engl J Med 1984:310:1545-1550.
55. Mertz GJ, Jones CC, Mills J, Fife KH, Lemon SM, Stapleton JT, Hill EL, Davis LG, and the Acyclovir Study Group: Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection: A mutlicentrc double-blind trial, JAMA 1988;260:201-206.
56. Mindel A, Faherty A, Carney O, Patou G, Freris M, Williams P: Dosage and safety of longterm suppressive acyclovir therapy for recurrent genital herpes, Lancet 1988:1:926-928.
57. Kaplowitz LG, Baker D, Gelb L, Blythe J, Hale R, Frost P, Crumpacker C, Ranovich S, Peacock JE, Herdon J, Davis LG, and the Acyclovir Study Group: Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infec-tion, JAMA 1991;256:747-751.
58. Carney O, Ross E, Ikkos G, Mindel A: The effect of suppressive acyclovir on the psychological morbidity associated with recurrent genital herpes, Genilourin Med 1993:69:457-459.
59. Barton S, Crooks J, and the International Val-ciclovir HSV Study Group: Once daily valaciclovir for prevention of genital herpes recurrences (abstract No, 4935), 20th International Congress of Chemotherapy, Sydney 1997.
60. Diaz-Miloma F, Sibbald RG, Shafran S, and the Collaborative Famciclovir Genital Herpes Suppression Group: Famciclovir suppression of recurrent gen ital herpes (abstract No, Milt), 36th Intersciencc Conference on Antimicrobial Agents and Chemotherapy, New Orleans 1996.
61. Mertz GJ, Loveless MO, Levin MJ, Kraus SJ, Fowler SL, Goade D, Tyring SK, and the Collaborative Famciclovir Genital Herpes Research Group: Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women, A multicenter, double-blind, place-bo-controlled trial, Arch Intern Med 1997:157: 343-349.
62. Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD Jr: Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes, Obstet Gynecol 1996:87:69-73.
63. Skoldenberg B, Alcstig K, Burrnan L, Forkman A, Levgren K, Norrby R, Sticrnsted G, Fors-gren M, Bergstrom T, Dahlqvist E, Frvden A, Norlin K, Olding-Stenkvist E, Uhnoo I, de Vahl K: Acyclovir versus vidarabine in herpes simplex encephalitis, Randomised multicentre study in consecutive Swedish patients, Lancet 1984;ii:707-711.
64. Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, Hanley D, Nahntias AJ, Soong SJ: Virarabine versus acyclovir therapy in herpes simplex encephalitis, N Engl J Med 1986:314:144-149.
65. Gutman LT, Wilfcrt CM, Eppes S: Herpes simplex virus encephalitis in children: Analysis of cerebrospinal fluid and progressive neurode-velopmcntal deterioration, J Infect Dis 1986: 154:415-421.
66. Preiser W, Weber B, Kids G, Fischer AP, Doerr HW: Unusual course of herpes simplex virus encephalitis after aciclovir therapy, Infection 1996:24:384-389.
67. Griffith PD: Progress in the clinical manage-men: of herpesvirus infections, Antiviral Chcnt Chemother 1995;6:191-209.
68. McKendall RR: Herpes simplex virus diseases: in McKendall RR, Stroop WG (eds): Handbook of Neurovirology, New York, Marcel Dekker 1994. pp 253-267.
69. Jackson WB, Breslin CW, Lorenzetti DW, Michaud R, Dube I: Treatment of herpes simplex keratitis: Comparison of acyclovir and vidara-binc, Can J Ophthalmol 1984:19:107-111.
70. Barron BA, Gee L, Hauck WW, Kurinij N, Dawson CR, Jones DB, Wilhelmus KR, Kaufman HE, Sugar J, Hyndiuk RA, Laibson PR, Stulting RD, Asbell PA, for the Herpetic Eye Disease Study Group: Herpetic eye disease study: A controlled trial of oral acyclovir for herpes simplex stromal keratitis, Ophthalmology 1994:101:1871-1882.
71. Colin J, Robinei A, Malel F: Preventive treatment of herpetic keratitis with acyclovir tablets, J Fr Ophthalmol 1993:16:6-9.
72. Balfour HH Jr, Kelly JM, Suarez CS, Heussncr RC, Englund JA, Crane DD, McGuirt PV, Clemmcr AF, Aeppli DM: Acyclovir treatment of varicella in otherwise healthy children, J Pcdiatr 1990:116:633-639.
73. Dunklc LM, Arvin MA, Whitley RJ, Rotbart HA, Feder HM Jr, Feldman S, Gcrshon Aa, Levy ML, Hayden GF, McGuirt PV, Harris J, Balfour Jr HH: A controlled trial of acyclovir for chicken pox in normal children, N Engl J Med 1991:325:1539-1544.
74. Balfour HH Jr, Rotbart HA, Feldman S, Dun-kle LM, Feder HM Jr, Prober CG, Hayden GF, Steinberg S, Whitley RJ, Goldberg L, McGuirt PV, and the Collaborative Acyclovir Varicella Study Group: Treatment of varicella in otherwise healthv adolescents, J Pediatr 1992:120: 627-633.
75. Wallace RM, Bowler WA, Murray NB, Brodine SK, Oldfield EC III: Treatment of adult varicella with oral acyclovir: A randomized, placebo controlled trial, Ann Intern Med 1992; 117: 358-363.
76. American Academy of Pediatrics Committee on Infectious Diseases: The use of oral acyclovir in otherwise healthy children with varicella, Pediatrics 1993:91:674-676.
77. Asano Y, Yoshikawa T, Suga S, Kobayashi I, Nakashima T, Yazaki T, Ozaki T, Yamada A, Imanishi J: Postexposure prophylaxis of varicella in family contact by oral acyclovir, Pediatrics 1993:92:219-222.
78. Haake DA, Zakowski PC, Haake DI, Bryson YJ: Early treatment with acyclovir for varicella pneumonia on otherwise healthy adults: Retrospective controlled study and review, Rev Infect Dis 1990:12:788-798.
79. Broussard RC, Payne K, George RB: Treatment with acyclovir of varicella pneumonia in pregnancy, Chest 1991:99:1045-1047.
80. Dworkin RH, Carrington D, Cunningham A, Kost RG, Levin MJ, McKcndrick MW, Ox-nian MN, Rentier B, Schmader KE, Tappciner G, Wassilew WS, Whitley RJ: Assessment of pain in herpes zoster: Lessons learned form antiviral trials, Antiviral Res 1997:33:73-85.
81. Meister W, Neiss A, Gross G, Docrr HW, Hobel W, Malin J-P, von Essen J, Reimann B-Y, Wittkc C, Wutzler P: Prognostic factors of postherpetic neuralgia in ambulatory patients, Intervirology, in press
82. Wutzler P, Doerr Il-W: Antivirale Thcrapie des Zoster, Chemother J 1997:6:134-135.
83. Peterslund NA, Seyer-Hansen, Ipsen J, Es-mann V, Schonhcyder H, Juhl H: Acyclovir in herpes zoster, Lancet 1981:ii:827-830.
84. Bean B, Braun C, Balfour HH Jr: Acyclovir therapy for acute herpes zoster, Lancet 1982:ii: 118-121.
85. Juel-Jcnsen BE, Khan JA, Pasvol G: High-dosc acyclovir in the treatment of zoster, A doubleblind, placebo-controlled trial, J Infect 1983: 6(suppl 1):31-36.
86. Huff JC, Bean B, Balfour HH Jr, Laskin OL, Connor JD, Corey L, Bryson YJ, McGuirt P: Therapy of herpes zoster with oral acyclovir, Am J Med 1988:85(suppl 2A):84-89.
87. Wood MJ, Ogan PJ, McKcndrick MW, Care CD, McGill JI, Webb EM: Efficacy of oral acyclovir in the treatment of acute herpes zoster, Am J Med 1988;85(suppl 2A):79-83.
88. Morton P, Thomson AN: Oral acyclovir on the treatment of herpes zoster in general practice, N Z Med J 1989:102:93-95.
89. Harding JC, Porter SM: Oral acyclovir in herpes zoster ophthalmicus, Curr Eye Res 1991:10:177-182.
90. Huff JC, Druckcr JL, Clcmmer A, Laskin OL, Connor JD, Bryson YJ, Balfour HH Jr: Effect of oral acyclovir on pain resolution in herpes zoster: A reanalysis, J Med Virol 1993:suppl 1: 93-96.
91. Crooks RJ, Jones DA, Fiddian AP: Zoster-associated chronic pain: An overview of clinical trials with acyclovir, Scand J Infect Dis Suppl 1991:80:62-68.
92. Wood MJ, Kay R, Dworkin RH, Soong S-J, Whitley RJ: Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: A meta-analysis of placebo-controlled trials, Clin Infect Dis 1996:22:341-347.
93. Beulner KB, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ: Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults, Antimicrob Agents Chcmother 1995:39: 1546-1553.
94. Carrington D: Valaciclovir and famciclovir under the clinical microscope - have improvements in antiviral efficacy been realized? Int Antiviral News 1997;5:55-57.
95. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marlev J, Heng M, Jones T, Rea T, Boon R, Saltzman R and the Colloaborativc Famciclovir Herpes Zoster Group: Famciclovir for the treatment of acute herpes zoster: Effects on acute disease and postherpetic neuralgia, Ann Intern Med 1995;123:89-96.
96. Degree H, Famciclovir Herpes Zoster Clinical Study Group: Famciclovir, a new oral antihcrpes drug: Results of the first controlled clinical study demonstrating its efficacy and safety on the treatment of uncomplicated herpes zoster in immunocompetent patients, Int J Antimicrob Agents 1994:4:241-246.
97. Carrington D: Reducing the duration of zoster-associated pain with famciclovir (abstract No, W 114), European Congress on Chemotherapy, Glasgow 1996.
98. Heidi M, Scholz H, Dbrffel W, Hermann J: Antiviral therapy of varicella-zostcr virus infection in immunocompromised children - A prospective randomized study of aciclovir versus brivudin, Infection 1991:19:401-405.
99. Bodsworth NJ, Boag F, Burdge D, Gencrcux M, Borleffs JC, Evans BA, Modai J, Colcbun-ders R, Thomas M, DeHertogh D, Pacelli L, Thomis J and the Multinational Sorivudine Study Group: Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults, J Infect Dis 1997:176:103-111.
100. Balfour HH Jr, Bean B, Laskin OL, Ambin-dcr RF, Meyers JD, Wade JC, Zaia JA, Acp-pli D, Kirk LE, Scgrcti AC, Keeney RE: Acyclovir halts progression of herpes zoster in immunocompromised patients, N Engl J Med 1983:308:1448-1453.
101. Balfour HH Jr, Benson C, Braun J, Cassens B, Erice A, Friedman-Kien A, Klein T, Polsky B, Safrin S: Management of acyclovir-resistant herpes simplex and varicella-zostcr virus infections, J Acquir Immune DeficSyndr 1994: 7:254-260.
102. Safrin S, Crumpacker C, Chatis P, Davis R, Hafncr R, Rush J, Kessler HA, Landry B, Mills J and other Members of the AIDS Clinical Trials Group: A controlled trial comparing foscamct with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome, N Engl J Med 1991:325:551-555
103. Safrin S, Kemmcrly S, Plotkin B, Smith T, Weissbach N, De Veratiez D, Phan LD, Cohn D: Foscarnet-resistant herpes simplex virus infection in patients with AIDS, J Infect Dis 1994:169:193-196.
104. Lalczari JP, Drew WL, Glutzcr E, Miner D, Safrin S, Owen WF Jr, Davidson JM, Fisher PE, Jaffe HS: Treatment with intravenous (S)-1 -(3-hydroxy-2-(phosphony!mcthoxy)-propyl)-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS, J Infect Dis 1994:170: 570-572.
105. Cinatl J Jr, C'inatl J, Rabenau H, Mainke M, Komhuber B, Doerr HW: Effect of aciclovir on the replication of herpes simplex virus type 1 in MA-104 cell line resistant to aciclovir, Arzneimittelforschung Drug Res 1992: 42:977-980.
106. Kessler HA, Hurwitz S, Farthing C, Benson CA, Feinberg J, Kuritzkes DS, Bailey TC, Safrin S, Stcigbigcl RT, Cheeseman SH, McKinley GF, Wettlaufs V, Owens S, Nevin T, Korvick JA and the AIDS Clinical Trial Group: Pilot study of topical trifiuridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172), J Acquir Immune Dcfic Svndr Hum Rctrovirol 1996:12:147-152.
107. Smith NA, Wood C, Asboe D, Bingham JS: Topical foscamet for aciclovir-resistant mucocutaneous herpes infections in AIDS, AIDS 1997:11:254-255.
108. Snoeck R, Andrei G, De Clercq E, Gerard M, Clumeck N, Tricot G, Sadzot-Delvaux C: A new topical treatment for resistant herpes simplex infections, Engl J Med 1993:329: 968-969.
109. Shcpp DH, Dandliker PS, Flournoy N, Meyers JD: Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients, Transplantation 1987;43:654-658.
110. Shaker T, Shaughnessy M, Barnum G, Sclke S, Zch J, Corey I,: Efficacy of famciclovir for suppressing HSV-2-infections among HIV positive persons (abstract) 3rd Conference on Retrovirus and Opportunistic Infections, Washington 1996.
111. Gold J, Bell A: Valacicloir prevents herpes simplex virus recurrences in HIV-infected individuals - A double-blind controlled trial (abstract No, 4935), 20th International Congress of Chemotherapy, Sydney 1997.
112. Cunningham AL, Dwyer DE: Advances and controversies in the antiviral therapy of herpes zoster, EurJ Clin Microbiol Infect Dis 1996:15:273-275.